lifestyle.wordsjournal.com

Author: ELI LILLY AND COMPANY

Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial

December 30, 2025
Lilly to participate in J.P. Morgan Healthcare Conference

December 17, 2025
Updated data for Lilly’s Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer

December 13, 2025
Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial

December 12, 2025
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama

December 10, 2025
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition

December 9, 2025
Lilly declares first-quarter 2026 dividend

December 8, 2025
Carolyn Bertozzi returns to Lilly board of directors

December 8, 2025
Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

November 14, 2025
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans

November 11, 2025